Abstract
Atrial fibrillation (AF) is the most common chronic arrhythmia and a source of significant morbidity and mortality. Previous studies have identified numerous risk factors for the development of AF, including hypertension, diabetes mellitus and heart failure, which have known pathophysiologic links with inflammatory processes. The importance of inflammation in inducing and perpetuating AF has been highlighted not only by experimental, epidemiological and cohort observational studies, but also by clinical trials providing evidence that inflammatory pathways are involved in AF pathogenesis. Local and systemic measurements of biomarkers and inflammatory mediators, as well as atrial biopsy studies have also given insight as to the purported relationship between this arrhythmia and inflammation. However, the link between inflammation and AF is still poorly defined and several issues remain unresolved. The present review offers an overview of existing evidence supporting the “inflammatory” hypothesis for AF pathophysiology and potential therapeutic means for counteracting this “foul interplay” between arrhythmia and inflammation.
Keywords: Anti-inflammatory, atrial fibrillation, CRP, inflammation, interleukin.
Medicinal Chemistry
Title:Inflammation Fueling Atrial Fibrillation Substrate: Seeking Ways to "Cool" the Heart
Volume: 10 Issue: 7
Author(s): Georgios Giannopoulos, Michael W. Cleman and Spyridon Deftereos
Affiliation:
Keywords: Anti-inflammatory, atrial fibrillation, CRP, inflammation, interleukin.
Abstract: Atrial fibrillation (AF) is the most common chronic arrhythmia and a source of significant morbidity and mortality. Previous studies have identified numerous risk factors for the development of AF, including hypertension, diabetes mellitus and heart failure, which have known pathophysiologic links with inflammatory processes. The importance of inflammation in inducing and perpetuating AF has been highlighted not only by experimental, epidemiological and cohort observational studies, but also by clinical trials providing evidence that inflammatory pathways are involved in AF pathogenesis. Local and systemic measurements of biomarkers and inflammatory mediators, as well as atrial biopsy studies have also given insight as to the purported relationship between this arrhythmia and inflammation. However, the link between inflammation and AF is still poorly defined and several issues remain unresolved. The present review offers an overview of existing evidence supporting the “inflammatory” hypothesis for AF pathophysiology and potential therapeutic means for counteracting this “foul interplay” between arrhythmia and inflammation.
Export Options
About this article
Cite this article as:
Giannopoulos Georgios, Cleman W. Michael and Deftereos Spyridon, Inflammation Fueling Atrial Fibrillation Substrate: Seeking Ways to "Cool" the Heart, Medicinal Chemistry 2014; 10 (7) . https://dx.doi.org/10.2174/1573406410666140318110100
DOI https://dx.doi.org/10.2174/1573406410666140318110100 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Wave Intensity Analysis in the Human Coronary Circulation in Health and Disease
Current Cardiology Reviews PCSK9 and LDLR The Yin-Yang in the Cellular Uptake of Cholesterol
Current Hypertension Reviews Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
Current Pharmaceutical Design Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
Current Gene Therapy Asymptomatic Lone Atrial Fibrillation - How can we Detect the Arrhythmia?
Current Pharmaceutical Design Targeting Mitochondria for Cardiac Protection
Current Drug Targets Understanding and Avoiding Antiretroviral Adverse Events
Current Pharmaceutical Design Editorial (Thematic Issue: All Roads of Renal Hypertension Lead to or Come from CKD)
Current Hypertension Reviews Coronary Calcium Risk Score and Cardiovascular Risk
Current Vascular Pharmacology Present Insights on Cardiomyopathy in Diabetic Patients
Current Diabetes Reviews Wharton's Jelly Mesenchymal Stem Cell Response on Chitosan-graft-poly (ε-caprolactone) Copolymer for Myocardium Tissue Engineering
Current Pharmaceutical Design HIV Infection and Myocardial Infarction
Current HIV Research A Review on the Use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis
Current Drug Targets The Etiology of Hypertension in the Metabolic Syndrome Part One: An Introduction to the History, the Concept and the Models
Current Vascular Pharmacology Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in Experimental Myocarditis
Current Pharmaceutical Design CETP Inhibitory Activity of Chlorobenzyl Benzamides: QPLD Docking, Pharmacophore Mapping and Synthesis
Letters in Drug Design & Discovery Current Treatment of Psoriasis with Biologics
Current Drug Discovery Technologies Long-Term Effectiveness and Safety Outcomes in HIV-1-Infected Patients After a Median Time of 6 Years on Nevirapine
Current HIV Research Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design Whole Cell Biocatalysts for the Preparation of Nucleosides and their Derivatives
Current Pharmaceutical Design